Publications and communications of Andy Chevigné

Largeot, A., Klapp, V., Viry, E., Gonder, S., Fernandez Botana, I., Blomme, A., Benzarti, M., Pierson, S., Duculty, C., Marttila, P., Wierz, M., Gargiulo, E., Pagano, G., An, N., El Hachem, N., Perez Hermandez, D., Chakraborty, S., Ysebaert, L., François, J.-H., ... Moussay, E. (2023). Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as therapeutic strategy in CLL. Blood. doi:10.1182/blood.2022017839

Isci, D., Veiga, D., Cokaiko, J., LOMBARD, A., Chevigné, A., ROGISTER, B., & Neirinckx, V. (10 April 2022). Study of the ACKR3/CXCR7 receptor in glioblastoma [Poster presentation]. Télévie Seminar, Liège, Belgium.

D'Uonnolo, G., Reynders, N., Meyrath, M., Abboud, D., Uchański, T., Laeremans, T., Volkman, B. F., Janji, B., Hanson, J., Szpakowska, M., & Chevigné, A. (2022). The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. Frontiers in Immunology, 13, 868579. doi:10.3389/fimmu.2022.868579

Isci, D.* , D'Uonnolo, G.* , Wantz, M., Rogister, B., LOMBARD, A., Chevigné, A., Szpakowska, M., & Neirinckx, V. (28 December 2021). Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma. Cancers, 14 (1), 130. doi:10.3390/cancers14010130
* These authors have contributed equally to this work.

Chevigné, A., Barumandzadeh, R., Groslambert, S., Cloes, B., Dehareng, D., Filée, P., Marx, J.-C., Frère, J.-M., Matagne, A., Jacquet, A., & Galleni, M. (16 November 2007). Relationship between propeptide pH unfolding and inhibitory ability during ProDer p 1 activation mechanism. Journal of Molecular Biology, 374 (1), 170-185. doi:10.1016/j.jmb.2007.08.025

Brans, A., Filée, P., Chevigné, A., Claessens, A., & Joris, B. (December 2004). New integrative method to generate Bacillus subtilis recombinant strains free of selection markers. Applied and Environmental Microbiology, 70 (12), 7241-7250. doi:10.1128/AEM.70.12.7241-7250.2004